Anthony Odell, who has been leading Tissue Regenix Group PLC for nearly a decade, is stepping down as CEO. His departure, announced Oct. 18, comes two months after he oversaw the closing of the regenerative medicine firm's acquisition of CellRight Technologies LLC (CRT), a young Texas start-up specializing in bone regeneration. (Also see "'Profitable, High-Growth' CellRight Bulks Up Tissue Regenix's Ortho Biz" - Medtech Insight, 20 July, 2017.).
Leeds, UK-based Tissue Regeneix told Medtech Insight that Odell had left with the agreement of the board of directors "as...
Welcome to Medtech Insight
Create an account to read this article
Already a subscriber?